Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
about
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.Chemosensitivity and p53; new tricks by an old dogGenomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapyOxazaphosphorines: new therapeutic strategies for an old class of drugs.TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.TP53 status and response to treatment in breast cancersTriple-negative breast cancer: are we making headway at least?Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors.Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.CMF revisited in the 21st century.Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Advances in the approach to novel drug clinical development for breast cancer.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.p53 as an Effector or Inhibitor of Therapy Response.Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway.TP53 Mutations in Breast and Ovarian Cancer.Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Distinct tumor protein p53 mutants in breast cancer subgroups.Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery.Translational opportunities for broad-spectrum natural phytochemicals and targeted agent combinations in breast cancer.18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.
P2860
Q27851827-E5E3E293-557C-4CE5-AFBA-86BABBBBB468Q33739325-C4B1A47A-1BBE-451A-8922-AB8D73391DF7Q33827045-4BB45C33-DBC5-43B0-8DC8-E8DAC192BBBDQ34113899-22EC7AF2-ED17-4AF0-87E9-91F743D85B99Q34234217-32CB2EB0-CF16-4C65-B12B-7BF49B05F786Q34576275-3D94E62B-B6AB-49CB-8B21-A05D5FBD7A07Q35043933-FA180301-6DC2-4450-899C-3578004297FCQ36061177-48D858B7-2F5B-4E23-B859-2FB37165C015Q36544248-96B31AD3-7BFE-43BB-B1DA-4233BEAD5CD7Q37650748-F425AD86-1806-4139-87BD-F65284FA9572Q37895805-02D8E13D-6B1C-481A-AA44-30290CEF5B20Q37933098-0F06A12C-01A1-480D-A398-55176977CABAQ38087850-DE3D057E-3A38-4F9F-9060-C77E5B1B305FQ38206546-39F4D123-B9AA-4E72-B302-9FEAE6D64F2FQ38647802-99E79050-BE20-4612-B717-32453FAB6E3BQ38659283-9EA3F99F-773F-453C-884E-89BABD0F3004Q38715267-901D2460-C062-4294-84B0-A45A56D26BA3Q38999130-078249DD-8CBA-4660-92BA-A5768E75023EQ40907746-782D7609-D7B4-40A8-A892-7A9A773AA9DDQ41519051-B5677490-A2D9-42E0-A4D1-6D6870FABE60Q42315543-D46D6821-8C6F-482D-A1AA-7027F8A2A5F8Q42511112-6D07AD7B-7E1C-4FF7-A2BE-0F2C0C272810Q47195056-175DCFE7-074D-4441-BD62-9F4FC9A52EF6Q47567895-E02BCB5C-C8A6-4C45-B2E6-BB209EF32D02Q52584340-793EFCE5-ED76-4CB9-BE7E-5C3DD07E194D
P2860
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Cyclophosphamide dose intensif ...... of p53 mutant breast cancers.
@ast
Cyclophosphamide dose intensif ...... of p53 mutant breast cancers.
@en
type
label
Cyclophosphamide dose intensif ...... of p53 mutant breast cancers.
@ast
Cyclophosphamide dose intensif ...... of p53 mutant breast cancers.
@en
prefLabel
Cyclophosphamide dose intensif ...... of p53 mutant breast cancers.
@ast
Cyclophosphamide dose intensif ...... of p53 mutant breast cancers.
@en
P2093
P2860
P50
P1433
P1476
Cyclophosphamide dose intensif ...... of p53 mutant breast cancers.
@en
P2093
Chafika Mazouni
Christine Desmedt
Christos Sotiriou
Elisabeth Turpin
Lajos Pusztai
Louis-François Plassa
Marc Espié
Martine Piccart
Michel Marty
Philippe Bertheau
P2860
P304
P356
10.1634/THEONCOLOGIST.2009-0243
P577
2010-03-12T00:00:00Z